What’s next for combinatorial therapy in mUC – CEC Oncology
CEC Oncology shared a post on X:
“What’s next for combinatorial therapy in mUC? Discover new possibilities in treatment with antibody-drug conjugates and take your practice to the next level.
Join Petros Grivas and Daniel Petrylak to earn free CME credit!
Book now.”
More posts featuring Petros Grivas and Daniel Petrylak.
Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
Daniel Petrylak, MD, is the Director of Genitourinary Oncology and Co-Director of the Signal Transduction Program at Yale University Cancer Center. Specializing in prostate, bladder, and kidney cancers, he focuses on developing innovative drug therapies. Prior to his role at Yale, Dr. Petrylak was the Director of Genitourinary Oncology at Columbia Presbyterian Medical Center and a Professor of Medicine at Columbia University Medical Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023